Journal Article

DKFZ-2024-01187

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study.

Mayén, A.-L. ; Sabra, M. ; Aglago, E. K. ; Perlemuter, G. ; Voican, C. ; Ramos, I. ; Debras, C. ; Blanco, J. ; Viallon, V. ; Ferrari, P. ; Olsen, A. ; Tjønneland, A. ; Langmann, F. ; Dahm, C. C. ; Rothwell, J. ; Laouali, N. ; Marques, C. ; Schulze, M. B. ; Katzke, V.DKFZ* ; Kaaks, R.DKFZ* ; Palli, D. ; Macciotta, A. ; Panico, S. ; Tumino, R. ; Agnoli, C. ; Farràs, M. ; Molina-Montes, E. ; Amiano, P. ; Chirlaque, M.-D. ; Castilla, J. ; Werner, M. ; Bodén, S. ; Heath, A. K. ; Tsilidis, K. ; Aune, D. ; Weiderpass, E. ; Freisling, H. ; Gunter, M. J. ; Jenab, M.

2024
Springer Heidelberg [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1186/s12916-024-03366-3

Abstract: Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS) are implicated in the aetiology of non-communicable diseases. Our study aimed to evaluate associations between NAFLD and MetS with overall and cause-specific mortality.We used dietary, lifestyle, anthropometric and metabolic biomarker data from a random subsample of 15,784 EPIC cohort participants. NAFLD was assessed using the fatty liver index (FLI) and MetS using the revised definition. Indices for metabolic dysfunction-associated fatty liver disease (MAFLD) were calculated. The individual associations of these indices with overall and cause-specific mortality were assessed using multivariable Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (95%CIs). As a subobjective, risk associations with adaptations of new classifications of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic and alcohol-related liver disease (MetALD) were also assessed.Among the 15,784 sub-cohort participants, a total of 1997 deaths occurred (835 due to cancer, 520 to CVD, 642 to other causes) over a median 15.6 (IQR, 12.3-17.1) years of follow-up. Compared to an FLI < 30, FLI ≥ 60 was associated with increased risks of overall mortality (HR = 1.44, 95%CI = 1.27-1.63), and deaths from cancer (HR = 1.32, 95%CI = 1.09-1.60), CVD (HR = 2.06, 95% CI = 1.61-2.63) or other causes (HR = 1.21, 95%CI = 0.97-1.51). Mortality risk associations were also elevated for individuals with MAFLD compared to those without. Individuals with MetS were at increased risk of all mortality endpoints, except cancer-specific mortality. MASLD and MetALD were associated with higher risk of overall mortality.Our findings based on a prospective cohort suggest that individuals with hepatic steatosis or metabolic dysfunction have a higher overall and cause-specific mortality risk.

Keyword(s): Humans (MeSH) ; Male (MeSH) ; Female (MeSH) ; Middle Aged (MeSH) ; Prospective Studies (MeSH) ; Metabolic Syndrome: mortality (MeSH) ; Non-alcoholic Fatty Liver Disease: mortality (MeSH) ; Adult (MeSH) ; Aged (MeSH) ; Risk Factors (MeSH) ; Cohort Studies (MeSH) ; Fatty Liver: mortality (MeSH) ; Hepatic steatosis ; MAFLD ; Metabolic syndrome ; Mortality ; Phenotypic NASH

---

Contributing Institute(s):

1. C020 Epidemiologie von Krebs (C020)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2024

---

Database coverage:
; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---